{
  "docId": "019de073-a45e-764e-97a1-b4793295a3f1",
  "docSlug": "90578b12d3108983c23425e7ddd95d83",
  "documentTitle": "ATAI | Investor Presentation Deck | 41 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 41,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a comparison structure to contrast safety/tolerability goals against efficacy goals.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a45e-764e-97a1-b4793295a3f1/17",
  "deckHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1",
  "deckJsonHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1.json",
  "deckAnchorHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Efficacy: Internal Product Goal: Rapid and sustained efficacy with ~2x/week dosing (comparable to other TRD therapies). Objective for this trial: Improvement in MADRS vs. placebo at 24 hours of ≥ 5 for a single dose",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "160a8f3c-114b-415c-b9b8-dfeace3b09f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "list",
      "text": "Safety/tolerability: Internal Product Goal: Differentiation from other TRD therapies with at-home, unsupervised use. Objective for this trial: Sedation (MOAA/S) and dissociation (CADSS) comparable to placebo, operationalized as risk ratio of < 2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9ce0249-e5a4-4caa-a373-89eb69bc4e30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "PCN-101 - Important to note: Redosing may increase magnitude of effect over time; Doses may be adjusted in future trials; Potentially less functional unblinding vs. ketamine/S-ketamine studies due to improved tolerability",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1a9fcd1-305a-4e94-8f95-0d1c9a5a41c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: MOAA/S = Modified Observer's Assessment of Alertness/Sedation. 1. Such as Singh et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression, Am J Psychiatry (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "685fed7b-61a2-458d-aa49-38d0055a1527",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "PCN-101 Phase 2a singe dose study designed to test the therapeutic index of R-ketamine against dissociation and severe sedation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ba26bf8-0d3a-4738-a83f-76759d18eaaf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 6,
      "beatId": "54d980bb-d331-41ca-8841-b0eb7beb049c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides a solution by showcasing ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 40,
      "from": 10,
      "beatId": "4c06d6d1-b3e1-4c1e-bceb-806b8f57a880",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides evidence and proof of the effectiveness of ATAI Life Sciences' treatments through various studies and data.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5cd92045-52c0-4b53-b15d-4dd6b345ff72",
      "evidence": "The presentation showcases ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 1,
      "objective": "How can we effectively treat mental health disorders?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}